Insurance Medicine

The incidence of melanoma is rising in much of the world, and it is now the fifth most commonly diagnosed cancer in North America.

Why do some COVID-19 patients experience critically low blood-oxygen readings? Why has mechanical ventilation been of varying benefit? RGA's Heather Lund explores these and other pertinent questions surrounding COVID-19-associated coagulation abnormalities. Insights shared and learned can only help to better understand, manage, and predict possible disease outcomes of this novel pathogen.

How can medical advancements extend a healthy lifespan and combat the diseases of old age?
 

Over the last several years, we have seen rapid advances in the technologies that aim to treat people with diabetes.

When cardiac events occur, such as a heart attack or the need for a revascularization procedure, there is quantifiable risk that can be identified and priced for.
 

Much is still unknown about the 2019 novel coronavirus (SARS-CoV-2). This document, created by Achim Regenauer, Chief Medical Officer PartnerRe, is intended only as a general overview. Opinions expressed are those of the author. Over the coming weeks and months, a much clearer picture of this virus and its impact is likely to emerge. We hope you find this information useful.

Nothing attracts media attention quite like a potential cure for cancer. Researchers from Cardiff University, UK, recently published this paper detailing one possible method to beat cancer with far-reaching, all-purpose abilities. While it is currently just a laboratory experiment, the method they have outlined certainly has merit.
 

As today’s medical and technological advances continue to be utilized and applied to Diabetes mellitus (DM), a newer and even more complex framework for the disease is emerging, which may help us further our understanding of it. RGA's Dr. Karneen Tam explores the most recent classification update and some of the newer thinking emerging about DM in Reinsurance News. 

Costing hundreds of thousands, even millions of USD per individual, a handful of immuno- and gene therapies have been developed to-date. But in fact it’s no longer correct to talk of just “a handful” – usage expansion is already well underway and set to increase medium term.

Dr. Karneen Tam, Medical Consultant, RGA Asia Pacific, provides an in-depth discussion on cardiovascular and kidney complications related to diabetes mellitus and the mitigating effects of newer classes of medication in ReFlections.